Compare Enveric Biosciences Inc (ENVB) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Norfolk Southern Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Norfolk Southern Corporation trades at $317.24 (market cap $70.35B). The key difference: Norfolk Southern Corporation is far larger — about 10515.7× Enveric Biosciences Inc's market cap, and Norfolk Southern Corporation pays a 1.72% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Norfolk Southern Corporation for 33 Days on average.
| ENVB | NSC | |
|---|---|---|
Market Cap | $6.69M | $70.35B |
Volume | 41,141 | 825,542 |
Sector | Health | Industrials |
52-Week High | $10.80 | $352.98 |
52-Week Low | $1.27 | $278.19 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | -$1.60M | $85.89B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Norfolk Southern (NSC) trades at $313.20, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.52 exceeding expectations by 6%. Valuation metrics include P/E of 26.72 and ROE of 16.97%, while the proposed Union Pacific merger progresses through regulatory review. Cash flow trends show operational strength with $4.36B from operations in 2025.
Outlook remains constructive with 43.75% analyst buy ratings and $361.86 consensus target offering 15.5% upside. Key risks include merger approval uncertainty and fuel cost pressures. The combination creates transcontinental railroad opportunities but faces STB regulatory hurdles. Earnings on October 22, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
